Wall Street analyst estimates for Serina Therapeutics, Inc. (SER): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-18 | $-0.34 | ||
| 2026-08-13 | $-0.55 | $-0.47 | -17.9% |
| 2026-05-14 | $-0.58 | $-0.44 | -31.8% |
| 2026-03-23 | $-0.31 | $-0.50 | +38.0% |
| 2025-11-13 | $-0.45 | $-0.47 | +4.3% |
| 2025-08-11 | $-0.66 | $-0.36 | -83.3% |
| 2025-05-08 | $-0.49 | $-0.62 | +21.0% |
| 2025-03-24 | $-0.27 | $0.42 | -164.3% |
Valuation Ratios
| Price / Book | 2.01 |
| EV / EBITDA | -0.95 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.4M | $1.4M | $1.7M | $54000 | $3.5M | $500000 | $3.2M | $56000 | 0 |
| Cost of Revenue | $911000 | $685000 | $841000 | $998500 | $1.3M | $3.8M | 0 | $90000 | $194000 | 0 |
| Gross Profit | $755000 | $719000 | $555000 | $729500 | -$1.2M | -$333840 | $500000 | $3.1M | -$138000 | 0 |
| Research & Development | $7.9M | $5.3M | $5.4M | $5.3M | $3.6M | $3.8M | $1.6M | $2.4M | $7.5M | $13.2M |
| Selling, General & Admin | $5.6M | $3.9M | $5.6M | $7.9M | $5.6M | $1.3M | $1.3M | $3.9M | $9.4M | $11.0M |
| Operating Expenses | $13.5M | $9.1M | $11.0M | $13.3M | $9.2M | $1.3M | $2.8M | $6.2M | $16.9M | $24.0M |
| Operating Income | -$12.7M | -$8.4M | -$10.4M | -$12.6M | -$10.4M | -$1.6M | -$2.3M | -$3.1M | -$17.0M | -$24.0M |
| EBITDA | -$11.9M | -$7.7M | -$7.2M | -$11.3M | -$8.7M | -$1.2M | -$2.6M | $5.9M | -$10.5M | -$18.9M |
| Interest Expense | $25000 | $12000 | 0 | 0 | $404000 | $3094 | $15878 | $558000 | $526000 | $213000 |
| Pre-tax Income | -$17.4M | -$6.6M | -$7.7M | -$12.2M | -$10.4M | -$1.3M | -$2.7M | $5.3M | -$11.2M | -$19.2M |
| Income Tax | 0 | 0 | 0 | $148000 | 0 | 0 | 0 | 0 | 0 | $18000 |
| Net Income | -$15.5M | -$6.6M | -$7.5M | -$12.2M | -$10.9M | -$1.3M | -$2.7M | $5.3M | -$11.1M | -$19.2M |
| EPS | $-15.21 | $-6.46 | $-7.56 | $-11.47 | $-10.14 | $-0.59 | $-2.49 | $0.63 | $-1.51 | $-1.91 |
| EPS (Diluted) | $-15.21 | $-6.46 | $-7.56 | $-11.47 | $-10.14 | $-0.59 | $-2.49 | $0.63 | $-1.51 | $-1.91 |
| Shares Outstanding (Diluted) | $1.0M | $1.0M | $992721 | $1.1M | $1.1M | $1.1M | $1.1M | $8.4M | $7.4M | $10.2M |
Price
| Price | $2.16 |
| Market Cap | $32M |
| Exchange | AMEX |
| Country | US |
Related companies: ALGS · BRNS · CVM · GNTA · GRCE · INMB · JUNS
Explore sector: Healthcare · Biotechnology
More sections of SER: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks